- Home
- JSPR vs ZYXI Comparison
JSPR vs ZYXI Comparison
Compare JSPR & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ZYXI
- Stock Information
- Founded
- JSPR 2018
- ZYXI 1996
- Country
- JSPR United States
- ZYXI United States
- Employees
- JSPR N/A
- ZYXI N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- JSPR Health Care
- ZYXI Health Care
- Exchange
- JSPR Nasdaq
- ZYXI Nasdaq
- Market Cap
- JSPR 47.6M
- ZYXI 44.8M
- IPO Year
- JSPR N/A
- ZYXI N/A
- Fundamental
- Price
- JSPR $2.45
- ZYXI $1.33
- Analyst Decision
- JSPR Buy
- ZYXI Hold
- Analyst Count
- JSPR 11
- ZYXI 3
- Target Price
- JSPR $28.00
- ZYXI $3.00
- AVG Volume (30 Days)
- JSPR 439.0K
- ZYXI 74.9K
- Earning Date
- JSPR 11-06-2025
- ZYXI 10-30-2025
- Dividend Yield
- JSPR N/A
- ZYXI N/A
- EPS Growth
- JSPR N/A
- ZYXI N/A
- EPS
- JSPR N/A
- ZYXI N/A
- Revenue
- JSPR N/A
- ZYXI $144,808,000.00
- Revenue This Year
- JSPR N/A
- ZYXI N/A
- Revenue Next Year
- JSPR N/A
- ZYXI $7.07
- P/E Ratio
- JSPR N/A
- ZYXI N/A
- Revenue Growth
- JSPR N/A
- ZYXI N/A
- 52 Week Low
- JSPR $2.22
- ZYXI $1.23
- 52 Week High
- JSPR $26.05
- ZYXI $9.42
- Technical
- Relative Strength Index (RSI)
- JSPR 46.88
- ZYXI 32.93
- Support Level
- JSPR $2.33
- ZYXI $1.42
- Resistance Level
- JSPR $2.65
- ZYXI $1.51
- Average True Range (ATR)
- JSPR 0.15
- ZYXI 0.06
- MACD
- JSPR 0.03
- ZYXI -0.00
- Stochastic Oscillator
- JSPR 53.32
- ZYXI 7.01
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.